Introduction {#sec1}
============

Human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), collectively known as human pluripotent stem cells (hPSCs), can potentially be differentiated into clinically useful cell types for in vitro disease modeling, drug screening, and cell replacement therapy. Given the explosion in diabetes and its complications worldwide, the directed differentiation of hPSCs into definitive endoderm (DE) and subsequently pancreatic cells is of immense interest ([@bib20]). In 2005, Novocell (now ViaCyte) reported the ability to derive \> 80% of DE from hESCs with the use of 100 ng/ml Activin A (hereafter referred to as "Activin") in the presence of 0.2%--2% fetal bovine serum (FBS; [@bib3]). To complement Activin/Nodal signaling in inducing DE formation, Wnt and BMP signaling activators were then introduced ([Table S1](#app2){ref-type="sec"} available online). Developmentally, this mimics the complex *Nodal*, *Wnt* (*Wnt3*, *Wnt3a* and *Wnt5a*) and *Bmp* (*Bmp4*) signaling, which operate during gastrulation, primitive streak, and early DE formation in the mouse embryo ([@bib1; @bib11; @bib12; @bib13; @bib18; @bib24]).

The coactivation of Wnt and Activin/Nodal signaling (albeit in the presence of FBS) is commonly used as described by [@bib4]. They reported that Activin and WNT3A (specifically 100 ng/ml Activin, 25 ng/ml WNT3A, and 0.2% FBS) can induce more than 80% of DE cells ([@bib4]). Alternatively, activation of Wnt signaling via the inhibition of glycogen synthase kinase (GSK)-3 (specifically 100 ng/ml Activin or 500 nM IDE1, 3 μM CHIR99021 \[GSK-3 inhibitor\], and 2% FBS) has also been recently reported to induce 70%--80% of DE cells ([@bib7; @bib10]). In contrast, the work of Teo, Dunn ([@bib14; @bib19]), and Vallier ([@bib23]) independently demonstrated that 10--50 ng/ml of BMP4 can synergistically act with Activin (in a defined medium without FBS) to induce more than 80% of DE cells. However, it is still uncertain how Wnt compares with BMP in cooperating with Activin/Nodal signaling in a chemically defined medium to induce DE formation.

We sought to clarify and define the Activin-Wnt-BMP signaling relationship using hiPSCs that we derived ([@bib21]). Here, we report a head-to-head comparison of Wnt versus BMP in combination with Activin signaling in a chemically defined medium without FBS to induce DE formation. Unlike previous reports (25 ng/ml WNT3A plus FBS; [Table S1](#app2){ref-type="sec"}), we observed that a high dose of WNT3A (100 ng/ml, without FBS) is required to maximally induce DE in the presence of 100 ng/ml Activin. The activation of Wnt signaling with the use of two independent GSK-3 inhibitors (CHIR99021 or 6-bromoindirubin-3′-oxime \[BIO\]; [@bib15]) or BMP signaling with BMP4 can also maximally induce DE cells. Thus, both Wnt and BMP signaling can effectively cooperate with Activin signaling to induce DE formation.

Effective differentiation of hPSCs into DE is coupled with the suppression of E-CADHERIN/CDH1 and pluripotency. Whereas BMP signaling has been reported to suppress E-CADHERIN/CDH1 and pluripotency ([@bib18; @bib19]), we observed that WNT3A is not as effective as GSK-3 inhibitors in suppressing both E-CADHERIN/CDH1 and the pluripotency program. This could partly explain the continued requirement for FBS when deriving DE with WNT3A. Therefore, our study identifies the unprecedented need for an additional compound to suppress pluripotency when combining Activin and WNT3A to generate DE cells without serum.

Results {#sec2}
=======

High Dose of WNT3A Is Sufficient to Cooperate with Activin to Induce DE without Serum {#sec2.1}
-------------------------------------------------------------------------------------

Many previous studies have reported reliance upon Activin, WNT3A, and FBS to differentiate hPSCs into DE ([Table S1](#app2){ref-type="sec"}). To determine whether WNT3A can cooperate with Activin in a chemically defined medium in the absence of serum (RPMI 2% B27) to induce DE from hiPSCs, we used 10--30 ng/ml WNT3A with 0--100 ng/ml Activin in optimization experiments. Dismally, 30 ng/ml WNT3A and 100 ng/ml Activin only marginally increase the expression of DE markers *SOX17* and *FOXA2* ([Figures 1](#fig1){ref-type="fig"}A and 1C--1E). Unlike previous reports, a low dose of WNT3A is insufficient to effectively promote DE formation in serum-free conditions. We subsequently increased the dose of WNT3A and determined that 100 ng/ml WNT3A can effectively result in maximal DE marker gene expression ([Figures 1](#fig1){ref-type="fig"}B--1E) without a dose-responsive increase in mesodermal markers *BRACHYURY* and *TBX6*, or extraembryonic marker *SOX7* ([Figure S1](#app2){ref-type="sec"}A). Morphologically, cells induced with 100 ng/ml Activin and 30 or 100 ng/ml WNT3A looked indistinguishable but different from no growth factor condition ([Figure 1](#fig1){ref-type="fig"}C). However, immunostaining and quantitative analyses for SOX17 DE marker clearly demonstrated that 100 ng/ml Activin + 100 ng/ml WNT3A gave rise to DE cells with a comparable efficiency as that of 100 ng/ml Activin + 30 ng/ml WNT3A + 0.5% FBS, as opposed to 100 ng/ml Activin + 30 ng/ml WNT3A ([Figures 1](#fig1){ref-type="fig"}D and 1E). Together, these findings suggest that FBS is necessary for synergistic activity with 100 ng/ml Activin and 25 ng/ml WNT3A to efficiently induce DE formation. Thus, FBS + 25 ng/ml WNT3A can be replaced with a high dose of WNT3A (100 ng/ml) to induce DE.

GSK-3 Inhibitors, CHIR99021 and BIO, Cooperate with Activin to Induce DE without Serum {#sec2.2}
--------------------------------------------------------------------------------------

To further define the synergism between Wnt and Activin signaling in inducing DE without serum, we adopted complementary approaches to activate Wnt signaling by inhibiting the downstream signaling molecule GSK-3, using two independent GSK-3 inhibitors, CHIR99021 or BIO, which block the degradation of β-catenin, thereby allowing its nuclear translocation and activation of downstream target genes. [@bib10] and [@bib7] used a GSK-3 inhibitor to demonstrate that 3 μM CHIR99021 with 100 ng/ml Activin or 500 nM IDE1 and 2% FBS induces 70%--80% of DE cells.

Initially, we used a range of doses of CHIR99021 (0.5, 3, or 9 μM) together with Activin to prompt DE differentiation ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, 9 μM CHIR99021 induces maximal *CXCR4* gene expression independent of the requirement for Activin. However, cardinal DE markers *EOMES*, *SOX17*, and *FOXA2* are suppressed at such a dose, suggesting that excessive Wnt signaling activation is refractory to DE formation ([Figure 2](#fig2){ref-type="fig"}A). Thus, we lowered the doses of CHIR99021 to 1, 3, and 5 μM. Morphologically, cells induced with 100 ng/ml Activin and 1 or 3 μM CHIR99021 were indistinguishable but different from no growth factor condition. We finally confirmed that 3 μM CHIR99021 (together with 100 ng/ml Activin) maximally induces DE differentiation in our chemically defined medium ([Figures 2](#fig2){ref-type="fig"}B and 2C) without a dose-responsive increase in mesodermal markers *BRACHYURY* and *TBX6*, or extraembryonic marker *SOX7* ([Figure S1](#app2){ref-type="sec"}B). The increasing dose of CHIR99021 increases mesodermal marker gene expression independent of the dose of Activin ([Figure S1](#app2){ref-type="sec"}B), indicating a fine balance in its use for DE (1--3 μM) versus mesoderm (\>3 μM) formation.

To complement the use of CHIR99021 in deriving DE cells, we used another GSK-3 inhibitor, BIO (0.5, 2, or 5 μM), to activate Wnt signaling and observed that ≥2 μM resulted in excessive cell death (data not shown). Subsequently we determined that 1.5 μM BIO together with 100 ng/ml Activin is optimal for generating DE cells from hPSCs without serum ([Figure 2](#fig2){ref-type="fig"}D), again without a dose-responsive increase in mesodermal markers *BRACHYURY* and *TBX6*, or extraembryonic marker *SOX7* ([Figure S1](#app2){ref-type="sec"}C).

Wnt and BMP Signaling Can Enhance Activin-Induced DE with Comparable Efficiencies without Serum Supplementation {#sec2.3}
---------------------------------------------------------------------------------------------------------------

Next, to confirm that BMP4 and Activin can induce DE from hPSCs without serum, we performed similar dose-response experiments. These experiments ascertained that 100 ng/ml Activin and 25--50 ng/ml BMP4 can elicit maximal expression of DE markers *CXCR4*, *SOX17*, and *FOXA2* ([Figure 3](#fig3){ref-type="fig"}A), without a dose-responsive increase in mesodermal markers *BRACHYURY* and *TBX6*, or extraembryonic marker *SOX7* ([Figure S1](#app2){ref-type="sec"}D). Because both Wnt and BMP can cooperate with Activin signaling to generate DE cells in our chemically defined differentiation condition, we then compared the various optimal DE-inducing conditions in the same experiment. Time course analyses indicated that Wnt and BMP signaling-based conditions induced a peak expression of mesendodermal marker *EOMES* between days 2 and 3 and DE markers *CXCR4* and *SOX17* on day 3 in one hiPSC and one hESC line ([Figures S2](#app2){ref-type="sec"}A--S2C). Thus, we compared these DE-inducing conditions on day 3 of differentiation.

Interestingly, the combination of 100 ng/ml Activin and 3 μM CHIR99021 resulted in the highest expression of mesendoderm (*EOMES*, *MIXL1*) and DE (*CXCR4*, *SOX17*, *FOXA2*) marker gene expression ([Figure 3](#fig3){ref-type="fig"}B), although the percentage of SOX17+ DE cells (as determined by cell count) is comparable with the other DE-inducing conditions ([Figures S3](#app2){ref-type="sec"}B and S3C). Fluorescence-activated cell sorting (FACS) analyses performed on two different hPSC lines further confirmed the observation that the various optimal DE-inducing conditions generated comparable percentages of CXCR4+SOX17+ DE cells ([Figures 3](#fig3){ref-type="fig"}C and [S3](#app2){ref-type="sec"}E). Reassuringly, cells differentiated in the optimal DE-inducing conditions morphologically resembled each other but were different from no growth factor condition ([Figure S3](#app2){ref-type="sec"}D). Among the optimal DE-inducing conditions, 3 μM CHIR99021 induced mesendodermal marker *BRACHYURY* and a marginal increase in mesodermal marker *TBX6* but none of them induced extraembryonic tissue marker *SOX7* dramatically ([Figure S3](#app2){ref-type="sec"}A).

To further ascertain that the various optimal DE-inducing conditions were comparable with published methods, we undertook a head-to-head comparison with protocols outlined in [@bib8] and [@bib22], using the same differentiation medium (RPMI 2% B27). Because [@bib22] utilized 20 ng/ml FGF2 (F20) and 10 μM LY294002 (LY10) in addition to Activin and BMP4, we applied the same amount of FGF2 and LY294002 to all our DE-inducing conditions because the aim was to determine if the various Wnt and BMP signaling-induced DE (in the presence of 100 ng/ml Activin) were comparable with published methods. In our comparison performed on two different hPSC lines, we found that our various optimal DE-inducing conditions were comparable with [@bib22] and at times superior to [@bib8] in terms of the induction of DE (*CXCR4*, *SOX17*, *FOXA2*) marker gene expression ([Figure S4](#app2){ref-type="sec"}A).

Next, we investigated whether our DE-inducing conditions generated DE derivatives comparably. To this end, we differentiated these DE cells into pancreatic progenitors using a published protocol ([@bib19]) with some modifications (A.K.K.T. et al., unpublished data). Our DE-inducing conditions gave rise to pancreatic progenitor markers *SOX9* and *PDX1* comparably with [@bib8] in two different hPSC lines ([Figure S4](#app2){ref-type="sec"}B), demonstrating equivalence in terms of their differentiation potential.

Wnt Signaling via WNT3A Is Not as Effective as BMP4 or the GSK-3 Inhibitors, CHIR99021 and BIO, in Suppressing E-CADHERIN and Pluripotency of hPSCs during DE Induction {#sec2.4}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

During DE differentiation, hPSCs undergo epithelial to mesenchymal transition evidenced by morphological changes ([Figures 1](#fig1){ref-type="fig"}C, [2](#fig2){ref-type="fig"}C, and [S3](#app2){ref-type="sec"}D) and a decrease in epithelial marker E-CADHERIN/CDH1 ([@bib3]). In addition, pluripotency program is suppressed, with rapid plummeting of pluripotency factor SOX2 expression followed by NANOG and lastly OCT4 ([@bib18; @bib19]). To ascertain that both Wnt and BMP signaling-induced DE cells are committed toward DE cell fate, we investigated the impact of varying doses of Wnt and BMP signaling activators on epithelial marker E-CADHERIN/CDH1 and pluripotency factor gene expression. Despite a high dose of WNT3A being able to significantly induce DE marker gene expression (with 100 ng/ml Activin), the expression level of E-CADHERIN/CDH1 did not decrease with increasing doses of WNT3A ([Figure 4](#fig4){ref-type="fig"}A). Surprisingly, pluripotency factors SOX2 and NANOG were only marginally affected by increasing doses of WNT3A with a background of 100 ng/ml Activin ([Figures 4](#fig4){ref-type="fig"}A--4C). In contrast, increasing doses of BMP4 and GSK-3 inhibitors, CHIR99021 and BIO, resulted in significant suppression of E-CADHERIN/CDH1 and pluripotency factors SOX2 and NANOG ([Figures 4](#fig4){ref-type="fig"}A--4C). Collectively, these data suggest that additional factors are required to work with WNT3A to suppress E-CADHERIN/CDH1 and pluripotency factors during differentiation toward DE. Therefore, CHIR99021, BMP4, and BIO may be preferred for DE differentiation because they also aid in the suppression of pluripotency ([Figures 4](#fig4){ref-type="fig"}A--4C).

Discussion {#sec3}
==========

We report the use of a chemically defined differentiation medium to compare DE-inducing effects by Wnt or BMP signaling in the presence of Activin signaling. This direct comparison demonstrates that both Wnt and BMP can independently synergize with Activin signaling to comparably and effectively induce DE cells from hPSCs in the absence of FBS. Numerous reports have established that 25 ng/ml WNT3A is optimal for inducing DE in the presence of Activin and FBS ([Table S1](#app2){ref-type="sec"}). However, 10--30 ng/ml WNT3A is insufficient to synergize with 100 ng/ml Activin to effectively generate DE cells in our serum-free system. The need for 100 ng/ml WNT3A for efficient DE formation in a chemically defined system suggests that FBS (which exhibits batch-to-batch variability) introduces additional differentiation-promoting factors to supplement 25 ng/ml WNT3A in inducing DE cells.

Although [@bib10] and [@bib7] used CHIR99021 to induce DE differentiation from hPSCs, they also included FBS in their protocol. We now provide several alternative methods for effectively inducing DE cells, all via the activation of Wnt signaling pathway (in addition to the indispensable Activin signaling pathway). These include 100 ng/ml WNT3A, 3 μM CHIR99021, and 1.5 μM BIO, all of which exhibit similar effects in DE induction. This three-pronged approach confirms the ability of Wnt to synergize with Activin signaling to induce DE in a chemically defined medium. Our comparison with [@bib8] (WNT3A-based) and [@bib22] (BMP4-based) further demonstrates that these three Wnt signaling-based optimized conditions induce DE comparably and efficiently, and give rise to DE derivatives with equivalent potential.

However, it is surprising to note that WNT3A is not as effective in downregulating E-CADHERIN/CDH1 and pluripotency factors as compared to GSK-3 inhibitors (or even BMP4) in a serum-free system. It is known from early mammalian development that the expression of *Oct4*, and in particular *Sox2* and *Nanog* ([@bib2; @bib6]) coincides with the in situ expression of *Wnt3*, *Wnt3a* and *Wnt5a* but not that of *Bmp4* ([@bib1; @bib12; @bib17; @bib18; @bib24]). Thus, given the overlapping expression of *Wnt* and pluripotency genes but not that of *Bmp*, it is conceivable that Wnt does not play a major role in suppressing pluripotency in contrast to BMP. In this study, we reveal fundamental mechanistic differences between the two developmental signaling pathways: (1) BMP signaling suppresses pluripotency and simultaneously promotes DE formation, whereas (2) Wnt signaling mostly serves to synergistically promote DE formation and may require additional factors to suppress pluripotency. FBS, which is commonly added in presence of WNT3A, could be promoting both differentiation and suppressing pluripotency.

Although the use of GSK-3 inhibitors results in a downregulation of E-CADHERIN/CDH1 and pluripotency factors SOX2 and NANOG, and GSK-3 inhibition activates downstream Wnt signaling, the inhibition of GSK-3 could potentially affect other signaling pathways in which GSK-3 is active, such as cellular proliferation and migration ([@bib5]). This is in contrast to the specific WNT3A-induced Wnt signaling. In our experiments, we also observed that WNT3A (up to 200 ng/ml) was not as effective as the GSK-3 inhibitors in elevating β-catenin transcript expression during DE differentiation (data not shown). This could imply that WNT3A-induced Wnt signaling events occurred solely at the protein level. Further, this suggests that GSK-3 inhibitors potentiate the increased presence of β-catenin, thereby strengthening Wnt signaling (besides inhibiting the GSK-3-containing destruction complex). Therefore, the inhibition of multi-functional GSK-3 coupled with the increased β-catenin expression could partly account for the differences observed between WNT3A-induced and GSK-3 inhibition-induced Wnt signaling. Specific to CHIR99021 (a potent and highly selective GSK-3 inhibitor as compared to BIO), the strong inductive effects on mesendodermal (*EOMES*, *MIXL1*, *BRACHYURY*) marker gene expression ([@bib9; @bib16]) and a marginal increase in mesodermal marker *TBX6* indicate that excessive Wnt signaling via CHIR99021 (\>3 μM) is likely to promote mesoderm while suppressing DE formation.

Taken together, CHIR99021 appears to be the preferred choice in combination with Activin (rank 1, [Figure 4](#fig4){ref-type="fig"}D) in generating DE cells based on its superior ability to induce mesendoderm as well as its cost effectiveness (∼2 cents/ml of media). BMP4 would be favored if not for its ∼20-fold greater cost (rank 2, [Figure 4](#fig4){ref-type="fig"}D), whereas BIO, although less expensive, exhibits cytotoxic effects (rank 3, [Figure 4](#fig4){ref-type="fig"}D) and WNT3A is both expensive and requires a high dose to be effective (rank 4, [Figure 4](#fig4){ref-type="fig"}D).

In summary, we demonstrate that both Wnt and BMP can cooperate with Activin signaling to induce DE with comparable efficiencies in a chemically defined serum-free medium. DE generated from both Wnt+Activin and BMP+Activin signaling can give rise to derivatives such as pancreatic progenitor cells ([@bib10; @bib19]). Thus, DE made via these two differing signaling pathways is conceptually consistent and physiologically relevant. Future genome-wide comparisons could reveal interesting mechanistic insights specific to Wnt and BMP signaling that are relevant for DE specification.

Experimental Procedures {#sec4}
=======================

Cell Culture {#sec4.1}
------------

hiPSCs derived from AG16102 skin fibroblasts (Coriell Institute) or hESCs (CHB8) were cultured in conditions as described previously ([@bib21]). To initiate DE differentiation, hiPSCs were treated with Collagenase IV and Dispase at 1:1 ratio for 3--5 min before being manually passaged into small clumps and placed in a 70 μm cell strainer to deplete the feeders ([@bib19]). hiPSCs were then differentiated 2 days later in RPMI 2% B27 (no vitamin A; serum-free chemically defined medium; [@bib19]) supplemented with the appropriate growth factors and chemical compounds. Cells were harvested after 3 days of differentiation. To generate pancreatic progenitors, DE was further differentiated with 50 ng/ml Activin for 2 days, 50 ng/ml fibroblast growth factor-2 (FGF2), 3 μM all-*trans* retinoic acid (RA), and 10 mM nicotinamide (NIC) for 5 days; 50 ng/ml FGF2, 3 μM RA, 10 mM NIC, and 20 μM DAPT for 4 days; and 50 ng/ml FGF2, 10 mM NIC, and 20 μM DAPT for 3 days.

qRT-PCR, Immunostaining, Western Blot, and FACS Analyses {#sec4.2}
--------------------------------------------------------

Methods for qRT-PCR, immunostaining, western blot, and FACS analyses have been described previously ([@bib19; @bib21]). The percentage of DE and pluripotent cells was obtained by dividing the number of SOX17+, SOX2+, and NANOG+ cells over the total number of DAPI+ cells. The average of three separate images was used for cell counting analyses. A p value \<0.05 indicates statistical significance by Student's t test. All error bars represent SD of three biological replicates in at least two independent experiments. Primers and antibodies are provided in [Table S2](#app2){ref-type="sec"}.

Supplemental Information {#app2}
========================

Document S1. Figures S1--S4 and Tables S1 and S2Document S2. Article plus Supplemental Information
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![A High Dose of WNT3A Is Required for Activin-Induced DE Formation in Absence of Serum\
(A and B) Expression of mesendoderm (*EOMES*, *MIXL1*) and DE (*CXCR4*, *SOX17*, *FOXA2*) markers in hiPSCs differentiated for 3 days in the presence of Activin (0, 25, 50, 100 ng/ml) and (A) low dose (10, 20, 30 ng/ml) or (B) high dose (50, 100, 200 ng/ml) of WNT3A. Asterisk (^∗^) indicates p \< 0.05 compared to no growth factor (A0 W0).\
(C) Morphology of hiPSCs differentiated for 3 days in the presence of no growth factors (A0 W0; left) or 100 ng/ml Activin (A100) plus either 30 ng/ml (W30; middle) or 100 ng/ml (W100; right) WNT3A. Scale bar represents 200 μm.\
(D) Immunostaining for the SOX17 DE marker on hiPSCs differentiated for 3 days in the presence of A100 and WNT3A (W0, W30, W100) ± 0.5% fetal bovine serum (FBS). Scale bar represents 50 μm.\
(E) The percentage of SOX17+ cells after differentiation of hiPSCs for 3 days in the presence of A100, A100 W30, A100 W100, or A100 W30 + 0.5% FBS. Asterisk (^∗^) indicates p \< 0.05 compared to A100 W0. All error bars represent SD of three biological replicates. A, Activin; W, WNT3A; and FBS, fetal bovine serum. DAPI is the nuclear stain.\
See also [Figure S1](#app2){ref-type="sec"}.](gr1){#fig1}

![GSK-3 Inhibitors CHIR99021 and BIO Can Promote DE Formation\
(A and B) Expression of mesendoderm (*EOMES*, *MIXL1*) and DE (*CXCR4*, *SOX17*, *FOXA2*) markers in hiPSCs differentiated for 3 days in the presence of Activin (0, 25, 50, 100 ng/ml) and (A) wide range (0.5, 3, 9 μM) or (B) narrow range (1, 3, 5 μM) of CHIR99021.\
(C) Morphology of hiPSCs differentiated for 3 days in the presence of no growth factors (A0 C0; left) or 100 ng/ml Activin (A100) plus either 1 μM (C1; middle) or 3 μM (C3; right) CHIR99021. Scale bar represents 200 μm.\
(D) Expression of mesendoderm and DE markers in hiPSCs differentiated for 3 days in the presence of Activin (0, 25, 50, 100 ng/ml) and BIO (0.5, 1, 1.5 μM). Asterisk (^∗^) indicates p \< 0.05 compared to no growth factor (A0 C0, A0 Bio0). All error bars represent SD of three biological replicates. A, Activin; C, CHIR99021.\
See also [Figure S1](#app2){ref-type="sec"}.](gr2){#fig2}

![Activators of Wnt and BMP Signaling Can Enhance Activin-Induced DE Formation with Comparable Efficiencies\
(A and B) Expression of mesendoderm (*EOMES*, *MIXL1*) and DE (*CXCR4*, *SOX17*, *FOXA2*) markers in hiPSCs differentiated for 3 days in the presence of (A) Activin (0, 25, 50, 100 ng/ml) and BMP4 (0, 25, 50 ng/ml) or (B) no growth factor (A0), 100 ng/ml Activin alone (A100), A100 plus either 25 ng/ml BMP4 (B25), 100 ng/ml WNT3A (W100), 3 μM CHIR99021 (C3), or 1.5 μM BIO (Bio1.5). Asterisk (^∗^) indicates p \< 0.05 compared to no growth factor (A0 B0, A0). All error bars represent SD of three biological replicates.\
(C) The percentage of CXCR4+SOX17+ DE cells determined by FACS analyses in undifferentiated hiPSCs or after differentiation of hiPSCs for 3 days in the presence of A100 B25, A100 W100, A100 C3, A100 Bio1.5, or A100 W30 + 0.5% FBS. A, Activin; B, BMP4; W, WNT3A; C, CHIR99021; FBS, fetal bovine serum.\
See also [Figures S1--S4](#app2){ref-type="sec"} and [Table S1](#app2){ref-type="sec"}.](gr3){#fig3}

![BMP4, CHIR99021 and BIO Are More Effective at Suppressing E-CADHERIN and Pluripotency as Compared to WNT3A\
(A) Western blot analyses for CDH1, SOX2, and ACTB protein levels in hiPSCs differentiated for 3 days in 100 ng/ml Activin A (A100) plus increasing doses of BMP4 (B), WNT3A (W), CHIR99021 (C), or BIO (Bio).\
(B) Immunostaining for SOX2 and NANOG pluripotency factors on hiPSCs differentiated for 3 days in the presence of A100 or A100 plus either 25 ng/ml BMP4 (B25), 100 ng/ml WNT3A (W100), 3 μM CHIR99021 (C3), 1.5 μM BIO (Bio1.5), or 30 ng/ml WNT3A (W30) + 0.5% fetal bovine serum (FBS). Scale bar represents 50 μm.\
(C) The percentage of SOX2+ and NANOG+ cells after differentiation of hiPSCs for 3 days in the presence of A100, A100 B25, A100 W100, A100 C3, A100 Bio1.5, or A100 W30 + 0.5% FBS. Asterisk (^∗^) indicates p \< 0.05 compared to A100. All error bars represent SD of three biological replicates.\
(D) Summary of growth factor combination choice for DE induction based on cost effectiveness. A100 C3 (rank 1) is preferred followed by A100 B25 (rank 2) and then A100 Bio1.5 (rank 3) or A100 W100 (rank 4). A100 is least preferred (rank 5). For every 1 ml of media, CHIR99021 costs ∼2 cents, BMP4 costs ∼48 cents, BIO costs ∼1 cent, and WNT3A costs ∼\$2.30. BIO is less preferred than BMP4 due to its cytotoxic effects. Scale bar represents 200 μm. A, Activin; B, BMP4; W, WNT3A; C, CHIR99021; FBS, fetal bovine serum; DE, definitive endoderm; and hPSC, human pluripotent stem cell. DAPI is the nuclear stain.](gr4){#fig4}
